The documents were needed to verify testing and manufacturing practices at Granules, a company in Telangana, India, that supplies generic medications to the U.S., officials say. More pharmaceutical ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued. Recent strategic ...

For instance, the price of AbbVie Inc. (NYSE:ABBV) stock is up an impressive 190% over the last five years. On top of that, the share price is up 22% in about a quarter. This could be related to ...

More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016 NORTH CHICAGO, Ill., Aug. 27, 2024 /PRNewswire ...

AbbVie shares are nearing $200, likely facing resistance and a potential pullback to test support between $175 and $185. Despite strong dividends and share buybacks, AbbVie’s higher P/E ratio ...

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy, especially as the market multiples look elevated from a historical perspective. Progress on its ...

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection. However, the shares look pricey at the moment. AbbVie is known as ...

AbbVie did not immediately respond to a request for comment, but has previously said it expects to retain a lower share of the Humira market next year. Pharmacy benefit managers, which act as ...